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Background: It is often difficult to diagnose salivary gland tumors that exhibit basaloid features differentially. The
aim of this study was to identify additional morphological and immunohistochemical characteristics that can aid
the diagnosis of basal cell adenocarcinoma (BCAC) of the salivary gland.
Methods and results: In total, 29 basal cell neoplasms [eight BCACs, 11 basal cell adenomas (BCAs) with capsular
invasion, and 10 BCAs without capsular invasion] and 10 cases of adenoid cystic carcinomas (ACCs) were subjected
to histopathology and immunohistochemical analyses for CK7, CK5/6, SMA, p63, calponin, p53, c-erbB2, CD117,
β-catenin, EGFR, VEGF, Ki-67, and S100P protein expression. Compared to BCA without capsular invasion, the BCACs
and BCAs with capsular invasion were more likely to be larger and have solid or cribriform patterns. Most BCACs
and BCAs exhibited nuclear β-catenin expression. In all basal cell neoplasm cases, the clinical course after surgery
with or without radiotherapy was indolent. β-catenin, CK5/6, CD117, and S100P protein were helpful for
differentiating basal cell neoplasms from ACC.
Conclusions: BCAs with capsular invasion shared several pathological features with BCACs, including a large size
and frequent cribriform patterns but the malignant potential of these tumors seems highly limited and should be
reexamined. β-catenin immunostaining may aid the differential diagnosis between basal cell neoplasms and ACCs.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9637819101988153
Keywords: Salivary gland neoplasm, Basal cell adenocarcinoma, Basal cell adenoma, β-catenin, Capsular invasionIntroduction
Basal cell adenocarcinoma (BCAC) is a rare malignant
tumor of the salivary gland that was included in the
1991 World Health Organization (WHO) classification.
To date, several studies and case reports that describe
this tumor have been published [1-13]. Despite this, a
solid consensus regarding the features that can be used
to distinguish BCAC from basal cell adenoma (BCA) has
not been obtained. In 2005, the WHO classification* Correspondence: kjc@amc.seoul.kr
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reproduction in any medium, provided the orsimply defined BCAC as being an infiltrative epithelial
neoplasm that is similar to BCA [14].
While BCAC can be distinguished from BCA on the
basis of the infiltration of tumor cells into the parotid par-
enchyma, dermis, skeletal muscle, or periglandular fat [14],
this infiltration is not severe because BCAC is essentially a
low-grade malignancy. Thus, it can be difficult to distin-
guish early stage BCACs from BCAs; it is also difficult to
distinguish BCACs from BCAs that exhibit minimal cap-
sular invasion. The diagnosis of BCACs is also hampered
by the fact that they can have a solid or cribriform pattern
that mimics the features of adenoid cystic carcinoma
(ACC). Although three studies have searched for immu-d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Cytokeratin 7 DAKO 1:400 Mouse
monoclonal
Cytokeratin 5/6 ZYMED 1:200 Mouse
monoclonal
SMA DAKO 1:400 Mouse
monoclonal
p63 NOVO 1:25 Mouse
monoclonal
calponin NEOMARKERS 1:3000 Mouse
monoclonal
p53 DAKO 1:3000 Mouse
monoclonal
c-erbB2 DAKO 1:500 Mouse
monoclonal
CD117 DAKO 1:400 Rabbit polyclonal
β-catenin ZYMED 1:2000 Mouse
monoclonal
EGFR ZYMED 1:100 Mouse
monoclonal
VEGF PHARMINGEN 1:500 Mouse
monoclonal
Ki-67 ZYMED 1:100 Mouse
monoclonal
S100P protein Protein tech 1:100 Rabbit polyclonal
EGFR, epidermal growth factor receptor; SMA, smooth muscle actin; VEGF,
vascular endothelial growth factor.
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BCAC, meaningful markers have not been found [3,8,12].
Thus, the present study sought to identify the clinical,
histopathological, and immunohistochemical characteris-




Two pathologists reviewed the surgical pathology files of
the Asan Medical Center for primary basaloid salivary
gland tumors that were diagnosed between 1993 and
2010. Tumors were only selected for analysis if they had
unequivocal basal cell features and an invasive growth
pattern at the periphery of the tumor, regardless of its
extent. We retrieved 19 cases. These 19 tumors had ini-
tially been diagnosed as BCAC (n=13), BCA (n=2), and
ACC (n=4). However, re-analysis of these cases revealed
that only eight met the histological requirements of
BCAC. The remaining 11 cases were classified on the
basis of current diagnostic criteria as BCA with capsular
invasion, although there remained some suspicion that
some of these tumors could be BCAC because of the
presence of capsular invasion. These 19 cases included
two cases that had been referred from outside hospitals.
Another 10 cases each of typical BCA without capsular
invasion and ACC that were diagnosed from 2009 to
2011 were also selected by the pathologists to serve as
comparators in the tissue microarray and immunohisto-
chemical analyses. The clinical data of all 39 cases were
obtained by reviewing the medical records.
Histopathologic examination
During the review of the slides, the two pathologists ana-
lyzed the architectural patterns (tubular, trabecular, solid,
cribriform, or membranous, mixed), mitotic counts, lymp-
hovascular or perineural invasion, and other notable
changes in the basal cell neoplasms (BCNs).
Immunohistochemical analysis
Formalin-fixed paraffin-embedded blocks were available
for 17 of the 19 BCAC and BCA with capsular invasion
cases (seven BCACs and 10 BCAs with capsular inva-
sion), the 10 BCA without capsular invasion cases, and
the 10 ACC cases. These blocks were not available for
the two referred cases. Tissue microarrays were gener-
ated from the blocks by using a manual tissue arrayer
(Pathology Devices, Westminster, MD, USA). Thus,
three 1.5 mm cores were taken from the donor blocks
and arrayed into recipient blocks. Thereafter, 4 μm tissue
microarray sections were subjected to immunoperoxidase
staining by using a Ventana autostainer and an ultra viewDAB detection kit (Ventana, Tucson, AZ, USA) according
to the manufacturer’s instructions. The primary antibodies
used in this study are listed in Table 1. Two observers then
analyzed the immunohistochemical reactivity to deter-
mine the staining patterns and intensity, and which cell
types were stained. The cytoplasmic immunostaining of
cytokeratin 7 (CK7), cytokeratin 5/6 (CK5/6), smooth
muscle actin (SMA), calponin, and vascular endothelial
growth factor (VEGF), the membranous/cytoplasmic stain-
ing of CD117, the nuclear staining of p63, p53, and S100P
protein, and the nuclear or cytoplasmic/membranous stain-
ing of β-catenin were graded as follows: negative (no stain-
ing or < 5% positive cells), focally positive (5–30% positive
cells), and diffusely positive (≥30% positive cells). EGFR and
c-erbB2 expression were evaluated on the basis of the
membrane staining pattern and intensity, as follows: nega-
tive (no staining, 0), weak (partial or weak complete mem-
brane staining, 1+), moderate (moderate membrane
staining, 2+), and strong (strong membrane staining, 3+).
A sample was deemed to be positive for EGFR or c-erbB2
expression if it showed moderate or strong membrane
staining. The nuclear and cytoplasmic/membranous
staining for β-catenin was assessed separately. Ki-67 ex-
pression was evaluated by calculating the Ki-67 labeling
index.
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To compare the different tumor types in terms of their
characteristics, t-tests were used with quantitative vari-
ables and Fisher exact tests were used with categorical
variables. A P-value of < 0.05 was considered to indicate
statistical significance. Statistical analysis was performed
by using SPSS version 18.
Results
Clinical characteristics
As shown in Table 2, six and two of the eight patients
with BCAC were female and male, respectively. This
group did not differ significantly from the BCA with and
without capsular invasion groups in terms of gender dis-
tribution, although there was a notable female predom-
inance in all BCN groups. The BCAC group was on
average 60.6 years old (range, 51–79 years), which meant
that this group was on average more than a decade older
than the patients with BCA with capsular invasion (47.9
years) and the patients with BCA without capsular inva-
sion (47.5 years). These differences between the BCAC
cases and the other two groups were statistically signifi-
cant (P < 0.05). All BCACs were located in the parotid
gland, showed a predilection for the left side (6:2). The
BCAC group did not differ significantly from the BCA
with and without capsular invasion groups in terms of
site. The BCACs were 3.5 cm in diameter on average
(range, 1.6–5.0 cm), while the BCAs with and without
capsular invasion were on average 3.1 and 1.9 cm, re-
spectively. The BCACs were significantly bigger than the
BCAs without capsular invasion (P < 0.001) but the dif-
ference between BCACs and BCAs with capsular inva-
sion did not achieve statistical significance.
All 29 patients with BCNs were initially treated by sur-
gery (Table 2). Twelve of the nineteen cases of BCAC
and BCA with capsular invasion (five BCACs and seven
BCAs with capsular invasion) also received postoperativeTable 2 Clinical characteristics of patients with basal cell neo
BCA
(n=8
Age (yrs) Mean (range) 61 (5
Sex Female/Male 6/2
Tumor size (cm) Mean (range) 3.5 (1
Site Parotid gland (Lt/Rt) 8 (6/
Submandibular gland 0
Treatment Surgery 3




BCAC, basal cell adenocarcinoma; BCA, basal cell adenoma; ci., capsular invasion; Ltradiotherapy. None of the BCAs without capsular inva-
sion received radiotherapy. None of the 19 patients with
BCAC or BCA with capsular invasion developed local
recurrences or distant metastases, and 18 have lived with
no evidence of disease for 27 to 233 months (mean, 90
months). The remaining patient had been diagnosed
with BCAC and died of subarachnoid hemorrhage from
a ruptured aneurysm 2 years after diagnosis. None of the
patients with BCA without capsular invasion died or had
recurrence.Microscopic analyses
Microscopic analysis revealed that the BCACs were
mostly encapsulated and had invasive areas at the per-
iphery that varied in extent but were mostly minimal
(Figure 1A). The BCAs with capsular invasion showed a
common pattern of invasion: small solid nests of tumor
cells that were streaming from the main mass caused at-
tenuation of moderate parts of the capsule (Figure 1B).
Another minimal capsular invasion pattern was charac-
terized by focal destruction of the capsule by tongue-like
projections or tumor cell buds that are continuous with
the main mass, while most of the capsule remains well-
preserved (Figure 1C).
The BCACs exhibited a mixture of growth patterns,
including tubular, trabecular, solid, membranous, and
cribriform (Table 3). The predominant architectural
growth pattern was solid (62.5%), followed by cribriform
(25%). Similarly, the predominant patterns in BCAs with
capsular invasion were solid and cribriform (these two
patterns accounted for 72.7% of these tumors). By con-
trast, in BCAs without capsular invasion, the trabecular
pattern predominated (60%) and the cribriform pattern
was not observed at all. The cribriform pattern in the
BCACs or BCAs with capsular invasion was character-
ized by large nests, large expansile lumens, and thinplasms
Cs BCAs with ci. BCAs without ci.
) (n=11) (n=10)
1–79) 48 (27–67) 48 (27–64)
8/3 9/1
.6–5.0) 3.1 (1.8–7.5) 1.9 (1.3–2.5)







, left; NED, no evidence of disease; Rt, right; RT, radiotherapy.
Figure 1 Histologic findings of basal cell adenocarcinoma and basal cell adenoma with capsular invasion. A. A basal cell adenocarcinoma
that is unencapsulated and is invading into the adjacent fat. B. A basal cell adenoma with capsular invasion. Variably-sized solid nests are
streaming from the solid component and are attenuating parts of the capsule. C. The cribriform variant of the basal cell adenoma with capsular
invasion shows a focal tongue-like projection into the capsule. D. The cribriform pattern of the basal cell adenocarcinoma with capsular invasion
mimics adenoid cystic carcinoma in that it presents with tumor islands with multiple holes. However, it does not show accompanying invasive
nests with true lumina, which are seen in adenoid cystic carcinoma. E. A basal cell adenocarcinoma that exhibits invasive growth with associated
perineural invasion. F. The solid form of basal cell adenocarcinoma. The tumor is composed of basaloid cells, which occur concomitantly with
vague two-cell morphologies and some palisading at the periphery.
Table 3 Pathological characteristics of basal cell neoplasms
BCACs BCAs with ci. BCAs without ci.
(n=8) (n=11) (n=10)
Predominant pattern Solid 5 (62.5%) 4 (36.4%) 3 (30.0%)
Cribriform 2 (25.0%) 4 (36.4%) 0 (0.0%)
Trabecular 0 (0.0%) 3 (27.3%) 6 (60.0%)
Tubular 1 (12.5%) 0 (0.0%) 1 (10.0%)
Mitosis > 4/10HPFs 1 (12.5%) 2 (18.2%) 0 (0.0%)
Perineural invasion 1 (12.5%) 0 (0.0%) 0 (0.0%)
Lymphovascular invasion 0 (0.0%) 0 (0.0%) 0 (0.0%)
Presence of daughter mass 3 (37.5%) 1 (9.1%) 0 (0.0%)
Cystic change 3 (37.5%) 3 (27.3%) 0 (0.0%)
Squamous differentiation 1 (12.5%) 1 (9.1%) 0 (0.0%)
BCAC, basal cell adenocarcinoma; BCA, basal cell adenoma; ci., capsular invasion; HPF, high power field.
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type (Figure 1D).
In terms of mitotic count, one of the eight BCACs and
two of the eleven BCAs with capsular invasion exhibited
more than four mitoses per ten high power fields
(Table 3). However, the mitotic count of these tumors
was generally low and none of these tumors showed ne-
crosis. Only one case of BCAC showed perineural inva-
sion (Figure 1E).
At the cytomorphological level, BCAC could not be
distinguished from BCA with or without capsular invasion.
These tumors consisted of relatively isomorphic basaloid
cells with little cytoplasm and elongated hyperchromatic
nuclei. The cells often displayed vague two-cell morpholo-
gies, especially in tubulotrabecular types. The peripherally
located cells tended to have more basophilic nuclei and
scant cytoplasms while the inner cells within the nests,
tubules, and cords tended to be more pale and plump.
This contrast was reminiscent of epithelial-myoepithelialFigure 2 Immunohistochemical findings of basal cell neoplasm and a
neoplasms for CK7 (A) and p63 (B) illustrate the pattern of epithelial-myoe
C. CK5/6 immunostaining reveals that most basal cell adenocarcinomas exh
pattern in adenoid cystic carcinoma. D. Nuclear β-catenin expression in a b
are negative for S100P protein, most adenoid cystic carcinomas show nucl
which is diffusely and strongly positive for CD117, basal cell adenocarcinomstructures, but the inner cells maintained the basaloid fea-
tures (thus differing from the eosinophilic tubular cells of
ACC) and the outer cells rarely exhibited clear cytoplasms.
The tumor cells in the solid cases were uniform with some
palisading at the periphery (Figure 1F).
Immunohistochemical analysis
All 27 BCNs that were subjected to immunohistochemical
analysis expressed CK7, SMA, p63, and calponin. The ex-
pression pattern of these epithelial or myoepithelial/basal
cell markers mimicked epithelial-myoepithelial differen-
tiation. The inner/luminal cells tended to express CK7
(Figure 2A) while the outer/peripheral cells expressed SMA
and p63 (Figure 2B). The expression pattern of calponin
was similar to that of SMA and p63 but the staining was
less intense and extensive.
All BCAC cell types were positive for CK5/6, which was
not observed for SMA, p63, and calponin (Figure 2C). In
addition, with the exception of one BCA with capsulardenoid cystic carcinoma. A & B. Immunostaining of basal cell
pithelial differentiation, especially in tubular or trabecular type tumors.
ibit diffuse cytoplasmic staining, which differs from the staining
asal cell adenocarcinoma. E. Unlike basal cell adenocarcinomas, which
ear expression of S100P protein. F. Unlike adenoid cystic carcinoma,
a shows focally and weakly to moderately positive CD117 staining.
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remaining BCNs expressed CK5/6 with a diffuse pattern
(Table 4). Some cases expressed CK5/6 more strongly in
peripherally located cells. Although all 10 ACCs also
expressed CK5/6, the positivity was mostly focal, and
mainly in the inner epithelial cells. This is interesting be-
cause CK5/6 is a myoepithelial/basal marker. The BCNs
not only differed from the ACCs in terms of CK5/6 ex-
pression, they also differed in nuclear β-catenin and
S100P protein expression. Thus, nuclear β-catenin was
expressed by 70–100% of the BCNs (Figure 2D) and 0% of
the ACCs, and S100P protein was expressed by 0–10% of
the BCNs but by 50% of the 10 ACCs (Figure 2E). With
regard to CD117, 57%, 60%, 100%, and 100% of the
BCAC, BCA with capsular invasion, BCA without capsu-
lar invasion, and ACC cases expressed this marker, re-
spectively (Figure 2F). However, this marker exhibited
focal CD117 expression in most BCNs whereas all ACCs
diffusely expressed CD117. In terms of p53, while only 3
of the 27 BCNs (11%) were focally positive for this marker,
6 of 10 ACCs (60%) were positive for it. Moreover, in all
ACCs, the Ki-67 labeling index exceeded 5% whereas
most BCNs had a low ki-67 labeling index (< 5%). All
BCNs and ACCs expressed VEGF, while none expressed
c-erbB2.
Discussion
Due to the low incidence of and insufficient information
on BCAC, it is often difficult to diagnose this tumor.
The WHO classification indicates that while BCAC is
cytologically and histomorphologically similar to BCA, it
is distinguished by the fact that it is also an infiltrative
epithelial neoplasm that has a potential for metastasis.
However, considering that it has now been officially ac-
cepted that pleomorphic adenoma has infiltrative and
metastatic potential, basal cell adenoma may also be
considered as an infiltrative neoplasm and the category
of BCAC can be questioned. Moreover, the current diag-
nostic criteria that are used to diagnose BCAC can beTable 4 Immunohistochemical characteristics of basal cell









Cytokeratin 5/6* 7 (100%) 9 (90%) 10 (100%) 3 (30%)
S100P protein 0 (0%) 1 (10%) 1 (10%) 5 (50%)
β-catenin** 7 (100%) 7 (70%) 10 (100%) 0 (0%)
CD117 4 (57%) 6 (60%) 10 (100%) 10 (100%)
EGFR 3 (43%) 2 (20%) 9 (90%) 5 (50%)
p53 0 (0%) 1 (10%) 2 (20%) 6 (60%)
Ki-67$ 0 (0%) 2 (20%) 2 (20%) 10 (100%)
*diffuse staining only; **nuclear staining only; $Ki-67 labeling index > 5%
ACC, adenoid cystic carcinoma; BCAC, basal cell adenocarcinoma; BCA, basal
cell adenoma; ci., capsular invasion; EGFR, epidermal growth factor receptor.impracticable because BCAC with extensive infiltrative
growth, such as into skeletal muscle or skin, is rarely
encountered.
In the present study, the infiltrative potential of all tu-
mors was regarded as being meaningful. Consequently, all
BCNs that showed invasion into the periphery, however
focal it might have been, were considered to be BCAC
candidates. The morphological, immunohistochemical,
and clinical differences of the BCNs according to the ex-
tent of invasion were then determined. With regard to
malignant potential, this could not be judged in the cases
with capsular or extracapsular invasion because none of
our patients manifested recurrences or metastases after
surgery with or without radiotherapy. However, the bio-
logical aggressiveness of BCAC needs to be reexamined,
because while regional recurrences or distant metastases
have been described since BCAC was first reported
[1,2,4,9-12], some authors have noted that certain cases
with recurrences or metastases have unusual histological
features that are seen in other similar tumors, such as
ACC [9,12]. In addition, most studies acknowledge that
BCAC is a very low-grade tumor [4,5]. One exception, the
study by Nagao et al., [10] found that BCAC had solid
morphology, a high Ki-67 labeling index, p53 overex-
pression, and poor behavior. The disparities between these
tumors and those in our and other studies cast doubt on
the true identity of the tumors of Nagao et al.
In the present study, the BCACs and BCAs with cap-
sular invasion were on average larger (3.5 and 3.1 cm,
respectively, with the largest tumor being 7.5 cm) than
the BCAs without capsular invasion (1.9 cm). However,
these groups did not exhibit any cytomorphological dif-
ferences. The only notable morphological dissimilarity
was that the BCACs and BCAs with capsular invasion
frequently had cribriform or solid growth patterns, un-
like the BCAs without capsular invasion. However, the
cribriform or solid patterns of BCAC can be misleading,
resulting in the misdiagnosis of ACC, which is much
more aggressive than BCAC. When the cribriform struc-
tures in BCACs were examined carefully, they were found
to differ from the cribriform structures in ACC, as they
had large expansile lumens, thin interluminal walls, bland
and uniform cells with elongated small nuclei, and lacked
definite two-cell populations. Moreover, the solid struc-
tures in BCACs were tightly apposed, often with jigsaw
puzzle pattern or peripheral palisading. By contrast,
solid variant ACC usually showed high-grade cytological
features, including marked nuclear atypia and frequent
mitoses.
To characterize BCAC immunohistochemically in the
present study, 13 antibodies against various markers
were used. While the BCACs, BCAs with capsular inva-
sion, and BCAs without capsular invasion did not have
clearly different profiles, S100P, β-catenin, CD117, and
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between BCNs and ACC. S100P protein has been pro-
posed to be an initiator of carcinogenesis and is reported
to play an important role in the malignant transform-
ation of ductal cells of pleomorphic adenoma [15,16].
Our analysis of S100P expression in BCNs and ACCs re-
vealed that most BCNs did not express this protein but
50% of ACCs showed nuclear S100P protein positivity,
albeit with varying extents. Thus, S100P may be a useful
marker for distinguishing ACCs from BCNs.
Various malignancies exhibit the nuclear expression of β-
catenin. Several studies have also shown that ACC and
other salivary gland tumors, such as epithelial-myoepithelial
carcinoma, pleomorphic adenoma, BCA, and BCAC, ex-
press β-catenin [17-20]. In particular, two studies showed
that BCA has nuclear β-catenin expression [17,18]. One of
these, by Kawahara et al., concluded that while nuclear β-
catenin expression may be a helpful marker for diagnosing
BCA, it is not useful in the differential diagnosis between
BCA and BCAC. They also showed that 154 other salivary
gland tumors, including ACC, do not have nuclear β-
catenin expression [18]. By contrast, two other studies
suggest that some ACCs do express nuclear β-catenin
[21,22]. Nevertheless, our results concur with the findings
of Kawahara et al. [18]: all ACCs were negative for nuclear
β-catenin staining, and all BCACs and BCAs without
capsular invasion, and most BCAs with capsular invasion
(7/10), showed nuclear positivity for β-catenin immuno-
staining. Interestingly, the three BCAs with capsular inva-
sion that did not show nuclear β-catenin staining had
higher mitotic activity (>10/10 HPFs) or apoptosis. Not-
ably, most BCNs and ACCs also showed cytoplasmic/
membranous positivity for β-catenin. It is generally well
known that activation of Wnt signaling increases the cyto-
plasmic levels of β-catenin, resulting in increased nuclear
β-catenin levels. A recent study of 45 salivary gland tu-
mors revealed that various benign and malignant salivary
gland tumors had cytoplasmic/membranous β-catenin
expression [20]. A mutation in CTNNB1 (the gene that
encodes β-catenin) may explain why BCAs show nuclear
β-catenin expression [18,22]. Thus, although the signifi-
cance of the nuclear expression of β-catenin in BCNs is
currently not clear, it may be useful for differentially diag-
nosing between BCNs and ACCs.
CD117 is a recently recognized marker of ACC [23,24].
Surprisingly, however, many BCNs showed membranous/
cytoplasmic CD117 positivity, some with weak to moder-
ate intensity. When Edwards et al. compared ACC and
monomorphic adenoma in terms of CD117 expression,
they concluded that it is not a useful marker for differen-
tial diagnosis [25]. In the present study, however, the stain-
ing intensity of CD117 expression was stronger in ACCs
than in BCNs, mainly in the luminal epithelial cells. Thus,
this marker may still be useful for the diagnosis of ACC.The present study showed that differential diagnosis
between BCA, BCAC, and ACC was unlikely to be aided
by the various epithelial and myoepithelial/basal cell
markers that were tested. However, unlike the other
markers, CK5/6 immunostaining indicated a difference
between BCNs and ACCs. The antibody mainly stained
the inner luminal cells of ACCs, whereas BCNs showed
a diffuse staining pattern. In the past, BCAs were con-
sidered to be “monomorphic and isocellular”, but it was
shown recently that they do not really lack myoepithelial
differentiation [13,26]. The results of the present study
with selected epithelial and myoepithelial markers were
not inconsistent with these arguments. However, the dif-
fuse expression of CK5/6 and lack of calponin expres-
sion in BCAs and BCACs may reflect the isomorphic
basal cell character of these tumors.
Analysis of the Ki-67 labeling index and p53 expres-
sion rate in the present study revealed both were higher
in ACCs than BCNs: while only 4 of 27 BCNs had a Ki-67
index > 5%, all ACCs had a Ki-67 index of approximately
20%. The BCACs also showed low p53 expression (< 5%),
which indicates the low-grade nature of this tumor.
Recently, Soave et al. studied expression of CD44 and
CD24 in malignant salivary gland tumors, and demon-
strated their relationship with tumor site and stage, but
did not provide differential diagnostic utility of CD44 and
CD24 [27]. They described weak membranous CD44 posi-
tivity in 2 of 5 BCAC.Conclusions
BCNs with an invasive periphery and definable BCACs
shared pathological features such as a large size, fre-
quent cribriform patterns, and the expression of various
proteins. However, BCNs without capsular penetration
remained difficult to diagnose, not only because of the
lack of invasive potential, but also because of the lack of
immunohistochemical or molecular evidence supporting
the notion that BCAs with capsular invasion may be
early BCACs. Given the clinical outcome of the 19 tu-
mors that had extracapsular or capsular invasion and
were larger than the BCAs without capsular invasion, it
can be concluded that BCAC is a low-grade tumor with
little propensity for metastasis or recurrence. This raises
doubt regarding the malignant potency of this tumor.
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